Dupilumab Provides Meaningful Clinical Responses in Harlequin Ichthyosis (ABCA12-nEDD)
A Report of Two Cases.
Chiramel MJ, Chen C, Siegfried E, Levy R
Pediatric DermatologyIn the feed 27 Jul 2026, published online 27 Jul 2026, issue 2026 Jul 27, added to PubMed 27 Jul 2026
Topics: Genetic skin diseaseChildrenBiologics
Abstract
Harlequin ichthyosis (HI) is a rare epidermal differentiation disorder characterized by thick hyperkeratotic plates, fissuring, and high neonatal morbidity. Long-term management remains challenging. We report two children with genetically confirmed HI who demonstrated meaningful improvement in pruritus, erythema, scaling, and overall well-being following dupilumab therapy, suggesting a potential role for IL-4/IL-13 blockade as an adjunct or alternative treatment in HI.
Abstract from PubMed
PMID 42508965 · DOI 10.1111/pde.70327